Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma
Aly‐Khan A. Lalani, Ziad Bakouny, Subrina Farah, Frede Donskov, Shaan Dudani, Daniel Y.C. Heng, Toni K. Choueiri
Abstract
An elevated body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) has been associated with an increased risk of renal cell carcinoma (RCC). 1 Previously, higher BMI was shown to be a positive prognostic factor for patients with metastatic clear cell RCC (mRCC) who were treated during the vascular endothelial growth factor (VEGF)-targeted therapy era. 2 However, the treatment landscape has shifted to include immune checkpoint inhibitors (ICIs) for most patients. We investigated t h i s o b e s it y p a r a d ox i n p at i e nt s w it h m RC C w h o were treated with programmed cell death 1 protein/ programmed cell death 1 ligand 1 (PD-1/PD-L1)-based ICIs and explored potential genomic alterations according to BMI status.